Imperial College London
Alternate

Professor Amin Hajitou

Faculty of Medicine, Department of Brain Sciences

Professor of Targeted Therapeutics
 
 
 
//

Contact

 

+44 (0)20 7594 6546a.hajitou Website

 
 
//

Location

 

Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chira:2018:10.1016/j.tibtech.2018.01.014,
author = {Chira, S and Gulei, D and Hajitou, A and Berindan-Neagoe, I},
doi = {10.1016/j.tibtech.2018.01.014},
journal = {Trends in Biotechnology},
pages = {653--660},
title = {Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9},
url = {http://dx.doi.org/10.1016/j.tibtech.2018.01.014},
volume = {36},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - With an increasing prevalence in the human population, cancer has become one of the most investigated fields of medicine. Among the potential targets for cancer therapy is the tumor suppressor gene TP53, which is found in a mutated state in approximately 50% of human cancers and is often associated with poor prognosis. We propose a novel, highly tumor-specific delivery system for TP53, based on the CRISPR/Cas9 genome editing technology. This system will restore the normal p53 phenotype in tumor cells by replacing the mutant TP53 gene with a functional copy, leading to sustained expression of p53 protein and tumor regression.
AU  - Chira,S
AU  - Gulei,D
AU  - Hajitou,A
AU  - Berindan-Neagoe,I
DO  - 10.1016/j.tibtech.2018.01.014
EP  - 660
PY  - 2018///
SN  - 0167-7799
SP  - 653
TI  - Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
T2  - Trends in Biotechnology
UR  - http://dx.doi.org/10.1016/j.tibtech.2018.01.014
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29478674
UR  - http://hdl.handle.net/10044/1/58377
VL  - 36
ER  -
Download